Choose Your Path
AI-Powered
Hyfe’s ResolveDTx pairs real-time, continuous cough monitoring with clinically proven-effective behavioral therapy. This combination helps pharma and life sciences teams transform chronic cough management, improve outcomes, and maximize ROI
ResolveDTx targets a large, underserved chronic cough market, leveraging first-mover advantage by combining continuous real-world cough measurement with digital therapy. Built on clinically validated technology and expert protocols, it delivers personalized care and demonstrable impact.
The only solution that tracks cough continuously in real-life conditions, built on Hyfe’s extensive clinical validation
Based on proven behavioral protocols (recommended by ATS and BTS), designed with the world’s leading expert, digitalized to reach patients at scale.
Personalized with onboard objective cough monitoring for real-time feedback. BCST shows 70% efficacy with symptom improvement typically in 1-2 weeks.
More engaged patients, measurable outcomes, and new models of care.
Amodularapproachtodigitalcoughcare.
Proven intervention for chronic cough, available as a whitelabeled, regulatory-ready DTx (Slovarp, L., et al "A Prospective decentralized investigation of the effect of a Cough Management feature inside a Wellness Application (CoughPro) in Refractory or Unexplained Chronic Cough (RCC/UCC)" [manuscript in preparation])
UCC/RCC have no safe, effective pharmacological treatments. An effective digital therapeutic meets an urgent unmet need.
Enhance the value of cough medications by improving adherence, persistence, and provider confidence.
ResolveDTx converts objective cough data and micro-interventions (techniques or actions aimed at helping coughers recognize and suppress the urge to cough early) into measurable improvements to amplify your drug’s performance in the real world.
Offer a seamless co-prescription that extends support beyond the pill, no change to the drug’s indication, just added value.
Added to the drug label as PDURS, with inputs (passive cough monitoring + in-app interactions) and outputs (trends, reminders, learning modules) described.
A right-sized evidence plan to demonstrate benefit for label inclusion and to power payer and access conversations.
An NDA supplement (sNDA), rather than a new combination-product submission, so you can move quickly while maintaining rigor.
Ready for combination or co-packaging strategies, increasing your pipeline’s attractiveness and differentiation. Plug-and-play components to elevate any portfolio.
Deploy ResolveDTx’s proven components - monitoring, engagement, coaching, analytics - into existing therapies or wellness platforms.
Seamlessly integrate digital elements into combination therapies, companion apps, or value-added services.
Increase attractiveness, differentiation, and real-world relevance across therapeutic areas.
If cough is impacting your patients and your retention, you have options today.
Cough hypersensitivity (often with laryngeal/neuronal drivers) is a treatable trait across asthma phenotypes. In CVA, residual cough can persist even when inflammation is controlled, undermining satisfaction and persistence. Patients whose asthma may be controlled still have out-of-control dry cough. ResolveDtx targets the Cough Hypersensitivity component with behavioral cough suppression therapy alongside standard care, reducing residual cough and supporting better adherence and longer on-therapy retention. PubMed
Cough frequency over time
Chronic cough often persists alongside productive morning cough and despite standard inhaled therapies; targeting cough hypersensitivity with behavioral therapy is clinically rational and can have health quality of life impact that will keep patients on track with their bronchodilators, antiinflammatories, and exercise programs. CHEST
Quality of live score
Activity restored Sleep quality improved
Adherence
Bronchodilators Anti-inflammatories Breathing exerciseCough reflex sensitivity can be heightened in lung cancer patients, especially during radiotherapy. Nerve-targeted antitussives have shown to relieve lung-cancer-related cough, supporting a hypersensitivity mechanism and pointing to behavioral therapy as a potentially valuable quality-of-life enhancement during and following treatment. PubMed, PubMed, PubMed
Cough Worsening During Radiotherapy
Cough reduction:
62% improvemen
Chronic cough is common and burdensome in ILD, with prevalence rates of 50%–89%. Neuronal sensitization, structural lung changes, and altered cough reflex regulation all contribute to persistent cough in ILD. Interventions that modulate the cough reflex (not by suppressing it pharmacologically but by modifying central/perceptual control) may help. Refractory cough in ILD significantly impairs quality of life, causing physical discomfort, social embarrassment, sleep disturbance, and psychological distress. Cough hypersensitivity symptoms are prevalent in ILD and detrimentally affect quality of life. Behavioral treatment can improve quality of life for many patients. CHEST
Sleep disturbance
Therapy sessions completed
Discover our full suite of products for research, digital therapeutics, and patient care.
Corporate hub: science, publications, investors, and strategic updates.
Cough diary for payers and healthcare organizations.
Continuous cough monitoring for clinical trials and pharma.
Consumer cough tracking app - empowering individuals worldwide.
Discover our suite of digital health solutions, from clinical research to patient care.
